Pharma Industry News
Printable Version   Email to a friend

Leptin May Help Maintain Weight Loss

December 20, 2005

The hormone leptin may help dieters at a steady weight, although it has not proven successful in assisting with weight loss per se, according to new research. In a recent study, injecting leptins twice daily in people with a recent 10% body-weight loss appeared to reverse many metabolic processes that promote weight regain.

The study, conducted by Michael Rosenbaum, MD, and colleagues at Columbia University, was published in the December 1, 2005 issue of the Journal of Clinical Investigation and reported by MedPage Today on December 2, 2005.

The hormone leptin is produced by fat cells and involved in metabolism and hunger regulation. Discovered in 1994 in mice, leptin was originally believed to hold promise in helping obese people to lose weight.

Although studies of leptin as a weight-loss treatment were unsuccessful, further investigations have revealed that leptin is involved in regulating many metabolic processes in which body that is losing weight tries to maintain and restore fat reserves, according to Dr Rosenbaum and colleagues.

The metabolic processes that complicate maintaining weight-loss include skeletal muscle work efficiency, sympathetic nervous system activity and the actions of certain thyroid hormones, according to the researchers.

Clinical Trial

The study involved five men and five women whose average age was 32 years. Three participants were obese and the other seven weighed within the normal range. All participants had maintained their maximum lifetime weight for at least six months.

Study participants underwent an induced 10% weight loss resulting from a restricted-calorie liquid formula diet. Following weight loss, participants received a liquid formula diet designed to maintain their weight, while the researchers measured markers of leptin-regulated metabolism.

Finally, participants received twice-daily leptin injections for five weeks, and the researchers monitored their weight and metabolism.

Participants' 10% weight loss was associated with a reduction in leptin levels and activation of various metabolic processes that tend to promote regaining weight, including increased skeletal muscle work efficiency, decreased sympathetic nervous system activity and reduced circulating thyroid-hormone levels.

Significantly, when the original leptin levels were restored via injections, these metabolic processes were reversed.

Although ultimate weight change was not an outcome measure, participants' averaged weight decreased further while they received leptin injections.

"These responses suggest that the weight-reduced state may be regarded as a condition of relative leptin insufficiency. Prevention of weight regain might be achievable by strategies relevant to reversing this leptin-insufficient state," the investigators concluded, noting that "studies of longer duration are needed to determine whether chronic reactivation of the leptin axis following weight loss might assist in the long-term maintenance of a reduced body weight."

Sources:
Leptin May Help Dieters Keep the Weight Off, MedPage Today, December 2, 2005.
Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. Rosenbaum M et al, Journal of Clinical Investigation, volume 115(12), pages 3579-3586, December 1, 2005.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
October 9, 2008
Audience: Pediatric and primary healthcare professionals, consumers [Posted 10/09/2008] FDA notified healthcare professionals and...
October 7, 2008
Audience: Pulmonary care health professionals and patients[UPDATE 10/07/2008] FDA informed healthcare professionals that FDA has...
October 3, 2008
Audience: Healthcare professionals, consumers [Posted 10/03/2008] FDA notified healthcare professionals of a Class I Recall of...
October 2, 2008
Audience: Physical medicine and rehabilitation specialists, anesthesia healthcare professionals, hospital surgical service...
More...
Latest Drug Information Updates

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

Navstel
Navstel is a balanced salt ophthalmic solution for use as an intraocular irrigation during surgical procedures involving perfusion of the eye.

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

More...